1. Birkmayer JG, Vrecko C, Volc D, Birkmayer W (1993) Nicotinamide adenine dinucleotide (NADH) — a new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol Scand [Suppl] 146: 32–35
2. Birkmayer W, Birkmayer GJ (1989) Nicotinamid-adenindinucleotide (NADH): the new approach in the therapy of Parkinson’s disease. Ann Clin Lab Sci 19: 38–43
3. Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E (1989) The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. J Neural Transm [PD Sect] 1: 297–302
4. Birkmayer W, Birkmayer JG, Vrecko K, Paletta B (1990) The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients. Adv Neurol 53: 545–549
5. Dizdar N, Kagedal B, Lindvall B (1994) Treatment of Parkinson’s disease with NADH. Acta Neurol Scand 90: 345–347